Table 1.

Characteristics of patients included in the selected studies.

Active Treatment	Study	Treatment	Patient Age, yrs (mean)	RA Duration, yrs (mean)	No. Anterior DMARD (mean)	HAQ Score (mean)	RF-positive^†, %	CRP, mg/dl (mean)
Infliximab	Maini, 1999²¹	Placebo	51	9	3.5	1.8	77	3.0
		Infliximab	56	8	3.8	1.8	84	3.1
	Schiff, 2008²²	Placebo	49	8	—	1.8	77	2.7
		Infliximab	49	7	—	1.7	85	3.3
	Westhovens, 2006²³	Placebo	52	8	—	1.5	81	1.2
		Infliximab	53	8	—	1.5	83	1.6
	Zhang, 2006²⁴	Placebo	49	8	—	—	—	—
		Infliximab	47	7	—	—	—	—
Etanercept	Weinblatt, 1999²⁵	Placebo	53	13	2.8	1.5	90	2.6
		Etanercept	48	13	2.7	1.5	84	2.2
	Combe, 2006²⁶	Placebo	53	6	2.3	1.6	—	1.2
		Etanercept	51	7	2.3	1.6	—	1.2
Adalimumab	Weinblatt, 2003²⁷	Placebo	56	11	—	1.6	—	3.1
		Adalimumab	57	12	—	1.6	—	2.1
	Keystone, 2004²⁸	Placebo	56	11	3.0	1.5	90	1.8
		Adalimumab	56	11	2.9	1.5	82	1.8
	Kim, 2007²⁹	Placebo	50	7	2.4	1.3	52	2.7
		Adalimumab	49	7	2.4	1.4	50	2.2
	Furst, 2003³⁰	Placebo	56	12	—	1.4	62	1.5
		Adalimumab	55	9	—	1.4	63	1.5
Golimumab	Keystone, 2009³¹	Placebo	52	7	—	1.3	81	0.8
		Golimumab	52	5	—	1.4	87	1.0
	Kay, 2008³²	Placebo	35	5	—	1.3	—	2.0
		Golimumab	35	6	—	1.7	—	2.1
Certolizumab pegol	Keystone, 2008⁵	Placebo	52	6	2.4	1.7	83	1.6
		Certolizumab pegol	51	6	2.3	1.7	80	1.6
	Smolen, 2009⁶	Placebo	52	6	2.2	1.6	78	1.4
		Certolizumab pegol	52	6	2.2	1.6	78	1.4
Anakinra	Cohen, 2004³³	Placebo	57	10	—	1.3	78	2.6
		Anakinra	56	11	—	1.4	76	2.7
Tocilizumab	Genovese, 2008³⁴	Placebo	54	9.8	1.6	1.5	—	2.6
		Tocilizumab	53	9.8	1.6	1.5	—	2.6
	Smolen, 2008³⁵	Placebo	51	8	1.7	1.5	71	2.4
		Tocilizumab	51	8	1.5	1.6	83	2.6
	Maini, 2006³⁶	Placebo	51	11	—	—	96	3.2
		Tocilizumab	50	11	—	—	80	2.4
	Kremer, 2009³⁷	Placebo	—	—	—	—	—	—
		Tocilizumab	—	—	—	—	—	—

DMARD: disease-modifying antirheumatic drug; CRP: C-reactive protein;
↵† RF-positive: patients positive for rheumatoid factor; HAQ: Health Assessment Questionnaire; RA: rheumatoid arthritis.